Sygnature Discovery, an integrated drug discovery contract research organization (CRO), reports that it completed a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. The company’s HTC platform has now doubled its synthesis and purification capacity—delivering twice the output in the same timeframe, according to Sygnature officials.
HTC platforms leverage automated systems to synthesize and purify large volumes of compounds. When integrated with Sygnature’s in-house high-throughput screening (HTS) platform—which evaluates compound libraries against biological targets—these technologies can accelerate the identification of promising drug candidates, noted a company spokesperson.
![Sygnature’s high-throughput chemistry platform has now doubled its synthesis and purification capacity, delivering twice the output in the same timeframe, according to company officials. [Sygnature Discovery]](https://www.genengnews.com/wp-content/uploads/2025/07/photo-of-part-of-htc-kit-1024x497.jpg)
A cornerstone of the investment is the integration of supercritical fluid chromatography (SFC) into Sygnature’s HTC platform. While SFC is becoming more prevalent, few HTC platforms use SFC for purification, explained Geraint Jones, director of chemistry, adding that Sygnature now offers both reverse-phase and SFC purification options, providing “flexibility and optimal purification conditions.” The upgraded facilities will be fully operational from August.
“This investment in our capabilities further enhances the value for our customers and reinforces our commitment to delivering cutting-edge services,” continued Jones. “Our customers want to partner with a CRO that will help them hit their milestones.”
The post Sygnature Discovery Completes Enhancement of High-Throughput Chemistry Facilities appeared first on GEN – Genetic Engineering and Biotechnology News.
